Literature DB >> 15774250

Treatment of benign prostatic hyperplasia and occurrence of prostatic surgery and acute urinary retention: a population-based cohort study in the Netherlands.

P C Souverein1, M M van Riemsdijk, J J M C H de la Rosette, P C E Opdam, H G M Leufkens.   

Abstract

OBJECTIVES: To assess and compare the risk of prostatic surgery in (subsets of) patients with a diagnosis of BPH. We sought to expand on data of an earlier pharmacy-based study by obtaining more information on BPH disease parameters by using a Dutch GP-based research database.
METHODS: A retrospective cohort study (1994-mid-year 2002) was conducted among 1430 men aged > or =45 years with > or =6 months of registration with the GP. BPH case identification was based on review of medical records.
RESULTS: Overall, we found that there was no difference in the risk of prostatic surgery between patients on medical treatment and watchful waiting. Patients using 5alpha-reductase inhibitors (5-ARIs) at any stage had a statistically significant reduced risk of surgery compared to patients using alpha-blockers only: adjusted hazard ratio 0.35 (95%CI: 0.13-0.96). The routine collection of BPH parameters were insufficient to be useful in the analysis.
CONCLUSION: Patients using 5-ARIs seemed to have a reduced risk of prostatic surgery compared to patients using alpha-blockers. However, it was unknown whether the disease profile of 5-ARI users is different compare to non-5-ARI-treated and untreated patients with BPH, as detailed medical information necessary to characterise patients according to the BPH disease severity and development of disease parameters is not routinely recorded by GPs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15774250     DOI: 10.1016/j.eururo.2004.11.001

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  8 in total

1.  Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men.

Authors:  Luca Cindolo; Luisella Pirozzi; Caterina Fanizza; Marilena Romero; Petros Sountoulides; Claus G Roehrborn; Vincenzo Mirone; Luigi Schips
Journal:  Int Urol Nephrol       Date:  2013-10-18       Impact factor: 2.370

2.  Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?

Authors:  Luca Cindolo; Luisella Pirozzi; Petros Sountoulides; Caterina Fanizza; Marilena Romero; Pietro Castellan; Alessandro Antonelli; Claudio Simeone; Andrea Tubaro; Cosimo de Nunzio; Luigi Schips
Journal:  BMC Urol       Date:  2015-09-21       Impact factor: 2.264

3.  Efficacy of bipolar "button" plasma vaporization of the prostate for benign prostatic obstruction, compared to the standard technique.

Authors:  Hamdy Aboutaleb
Journal:  Urol Ann       Date:  2015 Oct-Dec

4.  Bipolar transurethral enucleation of prostate versus photoselective vaporization for symptomatic benign prostatic hyperplasia (>70 ml).

Authors:  Xiao-Nan Mu; Si-Jun Wang; Ji Chen; Xun-Bo Jin; Zhong-Xian Huang; Long-Yang Zhang
Journal:  Asian J Androl       Date:  2017 Sep-Oct       Impact factor: 3.285

Review 5.  Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia.

Authors:  Neal Shore; Ronald Tutrone; Claus G Roehrborn
Journal:  Ther Adv Urol       Date:  2019-01-14

6.  Plasmakinetic enucleation of prostate versus 160-W laser photoselective vaporization for the treatment of benign prostatic hyperplasia.

Authors:  Si-Jun Wang; Xiao-Nan Mu; Ji Chen; Xun-Bo Jin; Shi-Bao Zhang; Long-Yang Zhang
Journal:  Asian J Androl       Date:  2017 Jan-Feb       Impact factor: 3.285

Review 7.  The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.

Authors:  Eric H Kim; John A Brockman; Gerald L Andriole
Journal:  Asian J Urol       Date:  2017-11-26

8.  Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement.

Authors:  Neal Shore; Ronald Tutrone; Mitchell Efros; Mohamed Bidair; Barton Wachs; Susan Kalota; Sheldon Freedman; James Bailen; Richard Levin; Stephen Richardson; Jed Kaminetsky; Jeffrey Snyder; Barry Shepard; Kenneth Goldberg; Alan Hay; Steven Gange; Ivan Grunberger
Journal:  World J Urol       Date:  2018-01-29       Impact factor: 4.226

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.